Overview

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Oncologico del Nord-Ovest
Treatments:
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin